Search Results 1711-1720 of 15987 for first%20aide%20basic

  1. Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients - Mayo Clinic

    A 50% increase in urine output with a 50% decrease in serum creatinine over the first 7 days post-transplant in subjects with slow or delayed graft function.

  2. A Study Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome - Mayo Clinic

    A Study Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome · Overview.

  3. A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection - Mayo Clinic

    There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent ...

  4. A Study of the Safety, Tolerability, and Drug/Body Interactions of C2N-8E12 in People with Progressive Supranuclear Palsy - Mayo Clinic

    ... first year of onset, as well as no evidence of other diseases that could explain these features. Probable PSP requires vertical supranuclear gaze palsy ...

  5. Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML - Mayo Clinic

    first early relapse after a remission duration of fewer than 6 months; or; relapse refractory to salvage combination therapy; or; second or subsequent relapse ...

  6. Lu AF82422 in participants with Multiple System Atrophy - Mayo Clinic

    The participant has taken any IMP 3 months or <5 half-lives of that product, whichever is longer, prior to the first dose of IMP. The participant is ...

  7. Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) - Mayo Clinic

    ... first dose of study medication and until 4 months after the last dose of study treatment. Exclusion Criteria: Life-threatening HES or life-threatening HES ...

  8. A Study to Create a Registry for Patients at High-Risk for Pancreatic Cancer - Mayo Clinic

    This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC).

  9. A Study of the Safety and Effectiveness of NP001 for Patients with Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation - Mayo Clinic

    Forced vital capacity greater than or equal to 65% of that predicted for age and height; Onset of ALS-related weakness less than 3 years prior to first dose of ...

  10. Cardiovascular Medicine - Clinical trials

    BAV is strongly associated with early development of aortic valve ... The patient comes first. So the mission and research here is to advance how ...